MARKET

GILD

GILD

Gilead Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

67.32
+0.71
+1.07%
Opening 10:16 06/21 EDT
OPEN
66.99
PREV CLOSE
66.61
HIGH
67.33
LOW
66.77
VOLUME
700.08K
TURNOVER
--
52 WEEK HIGH
78.94
52 WEEK LOW
56.56
MARKET CAP
84.43B
P/E (TTM)
327.11
1D
5D
1M
3M
1Y
5Y
Gilead's remdesivir reduces COVID-19 mortality risk- data
reuters.com · 1h ago
Verity & Verity, LLC Buys Crown Castle International Corp, Broadcom Inc, Algonquin Power ...
GuruFocus News · 1h ago
Gilead highlights positive data from remdesivir COVID-19 retrospective studies
Gilead Sciences (GILD) announces positive data from three retrospective studies of the real-world treatment of patients hospitalized with COVID-19 treated with Veklury (remdesivir).A reduction in mortality was observed across a spectrum
Seekingalpha · 1h ago
Gilead says real-world data show COVID-19 drug Veklury can reduce the risk of death
Shares of Gilead Sciences Inc. gained 0.3% in premarket trading on Monday after the drug manufacturer said retrospective research shows that Veklury, its COVID-19 treatment, reduces mortality among people who have been hospitalized with COVID-19. Veklury, ...
MarketWatch · 1h ago
BRIEF-Gilead’S Veklury® (Remdesivir) Associated With A Reduction In Mortality Rate In Hospitalized Patients With Covid-19 Across Three Analyses Of Large Retrospective Real-World Data Sets
reuters.com · 2h ago
Gilead's Veklury Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets
Gilead Sciences, Inc. (NASDAQ:GILD) today announced positive data from three retrospective studies of the real-world treatment of patients hospitalized with COVID-19, adding to the body of mortality and hospital
Benzinga · 2h ago
Gilead Sciences Says Veklury Lowers Mortality Rate in COVID-19 Treatment
MT Newswires · 4h ago
Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress(TM) 2021
--- One Late-Breaking, Six Oral Presentations and Posters across HDV, HCV, HBV, NASH and PSC Demonstrate the Breadth of Gilead's Commitment to People with Liver Disease -
Business Wire · 6h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GILD. Analyze the recent business situations of Gilead Sciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 31 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GILD stock price target is 74.49 with a high estimate of 100.00 and a low estimate of 60.00.
EPS
Institutional Holdings
Institutions: 2.22K
Institutional Holdings: 1.05B
% Owned: 83.90%
Shares Outstanding: 1.25B
TypeInstitutionsShares
Increased
617
56.37M
New
135
10.22M
Decreased
584
46.70M
Sold Out
122
8.33M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.02%
Pharmaceuticals & Medical Research
+0.70%
Key Executives
Chairman/Chief Executive Officer/Director
Daniel O'Day
Chief Financial Officer
Andrew Dickinson
Executive Vice President/General Counsel/Secretary
Brett Pletcher
Executive Vice President/Director of Human Resources
Katie Watson
Executive Vice President
Flavius Martin
Other
Johanna Mercier
Senior Vice President
Linda Higgins
Other
Merdad Parsey
Senior Vice President
Michael Quigley
Lead Director/Independent Director
Kevin Lofton
Independent Director
Jacqueline Barton
Independent Director
Jeffrey Bluestone
Independent Director
Sandra Horning
Independent Director
Kelly Kramer
Independent Director
Harish Manwani
Independent Director
Javier Rodriguez
Independent Director
Anthony Welters
Declaration Date
Dividend Per Share
Ex-Div Date
04/27/2021
Dividend USD 0.71
06/14/2021
02/04/2021
Dividend USD 0.71
03/12/2021
10/28/2020
Dividend USD 0.68
12/14/2020
07/30/2020
Dividend USD 0.68
09/14/2020
04/29/2020
Dividend USD 0.68
06/11/2020
02/03/2020
Dividend USD 0.68
03/12/2020
10/23/2019
Dividend USD 0.63
12/12/2019
07/29/2019
Dividend USD 0.63
09/12/2019
05/01/2019
Dividend USD 0.63
06/13/2019
02/01/2019
Dividend USD 0.63
03/14/2019
10/24/2018
Dividend USD 0.57
12/13/2018
07/24/2018
Dividend USD 0.57
09/13/2018
04/30/2018
Dividend USD 0.57
06/14/2018
02/05/2018
Dividend USD 0.57
03/15/2018
10/25/2017
Dividend USD 0.52
12/14/2017
07/25/2017
Dividend USD 0.52
09/14/2017
05/01/2017
Dividend USD 0.52
06/14/2017
02/06/2017
Dividend USD 0.52
03/14/2017
10/31/2016
Dividend USD 0.47
12/13/2016
07/22/2016
Dividend USD 0.47
09/14/2016
About GILD
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Webull offers kinds of Gilead Sciences, Inc. stock information, including NASDAQ:GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.